Immunotherapy for Skin Cancer

Overview

Journal Int Immunol

Specialty Allergy & Immunology

Date 2019 Feb 13

PMID 30753483

Citations 32

Authors

Kelly G Paulson

Miranda C Lahman

Aude G Chapuis

Isaac Brownell

Affiliations

Soon will be listed here.

Abstract

Among all tumor types, skin cancers are profoundly sensitive to immunotherapy. Indeed, the recently reported response rates for anti-PD-1 (anti-programmed-death 1) therapy for cutaneous malignant melanomas (MM), Merkel cell carcinomas, basal cell carcinomas, cutaneous squamous cell carcinomas and Kaposi sarcomas are all above 40%. This unique immunogenicity renders skin cancers as a paradigm for tumor-immune interactions and is driven by high mutational burdens, over-expressed tumor antigens and/or viral antigens. However, despite the clear demonstration of immunologic cure of skin cancer in some patients, most tumors develop either early (primary) or late (adaptive) resistance to immunotherapy. Resistance mechanisms are complex, and include contributions of tumor cell-intrinsic, T cell and microenvironment factors that have been recently further elucidated with the advent of single-cell technologies. This review will focus on the exciting progress with immunotherapy for skin cancers to date, and also our current understanding of the mechanisms of resistance to immunotherapy.

Citing Articles

Novel Silicon-Based Fluorescent Nanocomposite Drug Carriers for Natural Compound Delivery in Melanoma Treatment.

Gao F, Li L, Liu L, Li G, Zhang J, Zhan W J Fluoresc. 2025; .

PMID: 39992321 DOI: 10.1007/s10895-025-04182-5.

Exploring the Therapeutic Potential of Vesicular Nanocarrier Systems for Elimination of Skin Cancer.

Kumar L, Rana R, Komal K, Aggarwal V, Kumar S, Choudhary N Curr Med Chem. 2025; 32(2):258-285.

PMID: 39962707 DOI: 10.2174/0109298673297695240328074724.

Non-clinical evaluation of pmIL12 gene therapy for approval of the phase I clinical study.

Markelc B, Jesenko T, Brezar S, Omerzel M, Tratar U, Rencelj A Sci Rep. 2024; 14(1):22288.

PMID: 39333733 PMC: 11437156. DOI: 10.1038/s41598-024-73314-x.

Advanced and Metastatic Non-Melanoma Skin Cancer: Epidemiology, Risk Factors, Clinical Features, and Treatment Options.

Attal Z, Shalata W, Soklakova A, Tourkey L, Shalata S, Abu Saleh O Biomedicines. 2024; 12(7).

PMID: 39062023 PMC: 11274597. DOI: 10.3390/biomedicines12071448.

Porocarcinoma: Clinical and Histological Features, Immunohistochemistry and Outcomes: A Systematic Review.

Bienstman T, Guvenc C, Garmyn M Int J Mol Sci. 2024; 25(11).

PMID: 38891945 PMC: 11172007. DOI: 10.3390/ijms25115760.

References

Teulings H, Limpens J, Jansen S, Zwinderman A, Reitsma J, Spuls P . Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015; 33(7):773-81. DOI: 10.1200/JCO.2014.57.4756. View

Dudley M, Yang J, Sherry R, Hughes M, Royal R, Kammula U . Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008; 26(32):5233-9. PMC: 2652090. DOI: 10.1200/JCO.2008.16.5449. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Vilain R, Menzies A, Wilmott J, Kakavand H, Madore J, Guminski A . Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Clin Cancer Res. 2017; 23(17):5024-5033. DOI: 10.1158/1078-0432.CCR-16-0698. View

Gaiser M, Weis C, Gaiser T, Jiang H, Buder-Bakhaya K, Herpel E . Merkel cell carcinoma expresses the immunoregulatory ligand CD200 and induces immunosuppressive macrophages and regulatory T cells. Oncoimmunology. 2018; 7(5):e1426517. PMC: 5927480. DOI: 10.1080/2162402X.2018.1426517. View

Lardone R, Chan A, Lee A, Foshag L, Faries M, Sieling P . Bacillus Calmette-Guérin Alters Melanoma Microenvironment Favoring Antitumor T Cell Responses and Improving M2 Macrophage Function. Front Immunol. 2017; 8:965. PMC: 5554507. DOI: 10.3389/fimmu.2017.00965. View

Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H . Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA Dermatol. 2015; 152(1):45-51. DOI: 10.1001/jamadermatol.2015.2707. View

Uenami T, Hosono Y, Ishijima M, Kanazu M, Akazawa Y, Yano Y . Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report. Lung Cancer. 2017; 109:42-44. DOI: 10.1016/j.lungcan.2017.04.019. View

Andtbacka R, Kaufman H, Collichio F, Amatruda T, Senzer N, Chesney J . Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25):2780-8. DOI: 10.1200/JCO.2014.58.3377. View

10.

Chapuis A, Thompson J, Margolin K, Rodmyre R, Lai I, Dowdy K . Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A. 2012; 109(12):4592-7. PMC: 3311364. DOI: 10.1073/pnas.1113748109. View

11.

DAngelo S, Russell J, Lebbe C, Chmielowski B, Gambichler T, Grob J . Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. JAMA Oncol. 2018; 4(9):e180077. PMC: 5885245. DOI: 10.1001/jamaoncol.2018.0077. View

12.

Barry K, Hsu J, Broz M, Cueto F, Binnewies M, Combes A . A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018; 24(8):1178-1191. PMC: 6475503. DOI: 10.1038/s41591-018-0085-8. View

13.

Sade-Feldman M, Yizhak K, Bjorgaard S, Ray J, de Boer C, Jenkins R . Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018; 175(4):998-1013.e20. PMC: 6641984. DOI: 10.1016/j.cell.2018.10.038. View

14.

Wolchok J, Rollin L, Larkin J . Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017; 377(25):2503-2504. DOI: 10.1056/NEJMc1714339. View

15.

Grulich A, van Leeuwen M, Falster M, Vajdic C . Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007; 370(9581):59-67. DOI: 10.1016/S0140-6736(07)61050-2. View

16.

Beutner K, Geisse J, Helman D, Fox T, Ginkel A, Owens M . Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999; 41(6):1002-7. DOI: 10.1016/s0190-9622(99)70261-6. View

17.

Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Alcantara Luna S . Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol. 2015; 151(11):1206-1212. PMC: 5061067. DOI: 10.1001/jamadermatol.2015.1916. View

18.

Rogers H, Weinstock M, Feldman S, Coldiron B . Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. JAMA Dermatol. 2015; 151(10):1081-6. DOI: 10.1001/jamadermatol.2015.1187. View

19.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

20.

Rosenberg S . Future prospects for immunotherapy. Cancer. 1975; 36(2):821-4. DOI: 10.1002/1097-0142(197508)36:2+<821::aid-cncr2820360829>3.0.co;2-u. View